Skip to main content

Table 2 Drug classes addressed in formalised consensus

From: Effects of an interprofessional Quality Circle-Deprescribing Module (QC-DeMo) in Swiss nursing homes: a randomised controlled trial

Therapeutic class (ATC code)

Rationale for deprescribing a

Number of NH (%)

n = 26 b

Proton-pump inhibitors (A02BC)

Frequent overprescribing; side-effects in case of long-term use

21 (78%)

Lipid modifying agents (C10)

Negative risk/benefit ratio in people aged 85 or more if used in primary prevention

17 (63%)

Benzodiazepines (N05B & N05C)

Side effects in case of long-term use

10 (37%)

Urinary spasmolytics (G04BD) and anticholinergic drugs

Lack of efficacy (urinary spasmolytics); frequent side effects (all anticholinergics)

9 (33%)

Glucose-lowering drugs (A10B)

Higher HbA1C targets for very old patients; risk of adverse events if blood sugar too low

9 (33%)

Antihypertensives (C03, C07, C08, C09)

Higher blood pressure targets for very old patients

8 (30%)

Bisphosphonates (M05BA & M05BB)

Lack of evidence for efficacy after 5+ years of treatment

6 (22%)

Anti-dementia drugs (N06D)

Lack of efficacy; high costs

6 (22%)

Antidepressants (N06A)

Frequent overprescribing

6 (22%)

Antipsychotics (N05A)

Lack of evidence for use in behavioural and psychological symptoms of dementia

5 (19%)

  1. ATC Anatomic Therapeutic Chemical classification, NH nursing home, HbA1C glycated haemoglobin; n (% of column); a: as presented in the education session; b: 1 NH did not perform the intervention